Factors associated with anthracycline-induced cardiotoxicity in breast cancer patients

Authors

  • Elys María Pedraza-Rodríguez Universidad de Ciencias Médicas de Villa Clara. Facultad de Medicina https://orcid.org/0000-0002-6521-1541
  • Victor Ernesto González-Velázquez Universidad de Ciencias Médicas de Villa Clara. Facultad de Medicina
  • Lissi Lisbet Rodríguez-Rodríguez Universidad de Ciencias Médicas de Villa Clara. Hospital Oncológico Universitario “Celestino Hernández Robau”

Keywords:

Cardiotoxicity, Anthracyclines, Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions, Chemically-Induced Disorders

Abstract

Introduction: chemotherapy-induced heart disease is a common complication and the second leading cause of morbidity and mortality in cancer survivors.

Objective: to determine the factors associated with the onset of cardiotoxicity in breast cancer patients treated with anthracyclines at Celestino Hernández Robau Teaching Cancer Hospital during 2018.

Method: an observational, analytical, case-control study was conducted during the months of January 2018 to February 2019, at “Celestino Hernández Robau” Teaching Cancer Hospital, Villa Clara. The population was comprised of 89 patients with breast cancer diagnosed during 2018 treated with anthracyclines, from which a sample of 52 patients was chosen.

Results: there was a statistically significant relationship between variables such as history of high blood pressure (p=0,021, OR: 1,901, CI: 1,056-3,412), obesity (p=0,001, OR: 2,032, CI: 1,596-4,178), left ventricular hypertrophy (p=0,004, OR: 4,032; CI: 1,569-6,178), maximum corrected QT (p=0,073), diastolic dysfunction (p=0,025; OR 3,545; CI 1,346-5,687) and LVEF (p=0,012), which were associated with the occurrence of cardiotoxicity in the study sample.

Conclusions: history of hypertension, obesity, left ventricular hypertrophy and diastolic dysfunction, as well as LVEF and corrected QT values, predispose the appearance of cardiotoxicity in patients with breast cancer treated with anthracyclines.

Downloads

Download data is not yet available.

Author Biography

Lissi Lisbet Rodríguez-Rodríguez, Universidad de Ciencias Médicas de Villa Clara. Hospital Oncológico Universitario “Celestino Hernández Robau”

Máster en Longevidad Satisfactoria. Especialista de II Grado en Oncología. Profesor auxiliar.

References

1. Nwuruku GC, Martínez JAP, Arca ÁMC, Álvarez OM, Tamayo JB, Hernández RAG. Detección precoz de cardiotoxicidad inducida por antraciclinas. CorSalud [Internet]. 3 de julio de 2014 [citado 2019 Sep 26];6(3):229-34. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/159

2. Sánchez MD, Milián MB. Repolarización ventricular en la terapia oncológica. CorSalud [Internet]. 2019 [citado 2019 Nov 30];11(2):146-152. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/download/462/864

3. López-Fernández T, Thavendiranathan P. Nuevas técnicas de imagen cardiaca en la detección precoz de cardiotoxicidad secundaria a tratamientos oncológicos. Revista Española de Cardiología [Internet]. 1 de junio de 2017 [citado 2019 Sep 26];70(6):487-95. Disponible en: http://www.sciencedirect.com/science/article/pii/S0300893217300507

4. Cruz M, Duarte-Rodrigues J, Campelo M. Cardiotoxicidade na terapêutica com antraciclinas: estratégias de prevenção. Revista Portuguesa de Cardiologia [Internet]. 1 de junio de 2016 [citado 2019 Sep 26];35(6):359-71. Disponible en: http://www.sciencedirect.com/science/article/pii/S0870255116000627

5. Vicente-Hernández B, Sarre-Álvarez D, Rodríguez-Weber FL, Díaz-Greene EJ. Cardiotoxicidad por antracíclicos. Medicina Interna de Mexico. [Internet]. 9 de octubre de 2015 [citado 2019 Sep 27];31(5):567-77. Disponible en: https://www.medigraphic.com/pdfs/medintmex/mim-2015/mim155j.pdf

6. Monsuez JJ, Charniot JC, Vighat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiology. [Internet]. 2010 [citado 2019 Sep 27];144(1):3-15. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0167527310001786

7. Pedraza-Rodríguez EM, González-Velázquez VE, Medina-Morales JI, Rodríguez-Rodríguez LL. Caracterización clínica del dolor y la calidad de vida en pacientes con tumores malignos. Universidad Médica Pinareña [Internet]. 2 de mayo de 2019 [citado 2019 Sep 27];15(2):233-241. Disponible en: http://galeno.pri.sld.cu/index.php/galeno/article/download/601/pdf

8. Anuario Estadístico de Salud 2017. La Habana: Ministerio de Salud Pública, Dirección de Registros Médicos y Estadísticas en Salud. [Internet]. 2018. [citado 2019 Oct 14]. Disponible en: http://bvscuba.sld.cu/anuario-estadistico-de-cuba/

9. Parma G, Lluberas N, Castillo C, Ormaechea G. Quimioterápicos y Cardiotoxicidad: un enfoque actual y práctico para el clínico de una disciplina en pleno desarrollo. Archivos de Medicina Interna [Internet]. julio de 2013 [citado 2019 Oct 14];35(2):38-47. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_abstract&pid=S1688-423X2013000200003&lng=es&nrm=iso&tlng=en

10. Salazar L, Palacio AC, Rodríguez JR. Mecanismos de cardiotoxicidad: antineoplásicos, anti-inflamatorios no esteroideos, antipsicóticos, cocaetileno y simpaticomiméticos. Revista Colombiana de Cardiología [Internet]. 1 de marzo de 2011 [citado 2019 Oct 14];18(2):100-10. Disponible en: http://www.sciencedirect.com/science/article/pii/S0120563311701723

11. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer Cardio-Oncology. Mayo Clin Proc. [Internet]. 2014 [citado 2019 Oct 15];89(9) 1287-306. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0025619614004753

12. Ramos MAR. Estratificación del riesgo de cardiotoxicidad inducida por quimioterapia. CorSalud [Internet]. 10 de febrero de 2019 [citado 2019 Oct 15];10(4):341-2. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/392

13. Pérez-Topete SE, Miranda-Aquino T, Muñoz-Ramírez M del R, Barrientos-Quintanilla LA, Calderón JA, Herrera E. Cardiomiopatía inducida por antraciclinas y choque séptico secundario a colitis neutropénica. Med Int Mex [Internet]. 15 de junio de 2016 [citado 2019 Oct 15];32(2):256-9. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=65815

14. Sáez GC, Hernández NEB, Tamayo FDP, Santos AV de la T. Evaluación cardiaca de pacientes con cáncer de mama tratadas con antraciclinas. Revista Cubana de Cardiología y Cirugía Cardiovascular [Internet]. 10 de marzo de 2017 [citado 2019 Oct 26];23(1):266-71. Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/679

15. Yera RAM, Pérez LS, Díaz AT. Cardiotoxicidad inducida por quimioterapia. CorSalud [Internet]. 13 de abril de 2018 [citado 2019 Oct 26];10(1):68-77. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/295

16. Fariñas LDLCR, Puerta RC, Machado RL. Alteraciones electrocardiográficas en pacientes adultos mayores hospitalizados CorSalud [Internet]. 2019 [citado 2019 Nov 30];11(2):129-138. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/viewFile/463/865#page=38

17. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, y colaboradores. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. [Internet]. 2014 [citado 2019 Dic 12];27(9):91139. [Internet]. [citado 2019 Sep 26]. Disponible en: https://academic.oup.com/ehjcimaging/article/15/10/1063/2397309

Downloads

Published

2020-01-09

How to Cite

1.
Pedraza-Rodríguez EM, González-Velázquez VE, Rodríguez-Rodríguez LL. Factors associated with anthracycline-induced cardiotoxicity in breast cancer patients. Univ. Méd. Pinareña [Internet]. 2020 Jan. 9 [cited 2025 Apr. 15];16(1):e383. Available from: https://revgaleno.sld.cu/index.php/ump/article/view/383

Issue

Vol. 16 No. 1 (2020): Enero-Abril

Section

Original Article

License

Authors who have published with this journal accept the following terms: authors will retain their copyright and guarantee the journal the right of first publication of their work, which will be simultaneously subject to the Creative Commons recognition license that allows third parties to share the work as long as its author is indicated and its first publication is this journal. Authors may adopt other non-exclusive license agreements for the distribution of the version of the published article (e.g., deposit it in an institutional telematic archive or publish it in a monographic volume) provided that the initial publication in this journal is indicated. Authors are permitted and encouraged to disseminate their article using Internet (e.g., in institutional telematic archives or on their website) before and during the submission process, which may lead to interesting exchanges and increased citations of the published work. (See The Effect of Open Access).

Most read articles by the same author(s)